Federal - HR 5002

A bill to expand the unique research initiatives authority of the National Institutes of Health.

Introduced

February 13, 2018

Description

A bill to expand the unique research initiatives authority of the National Institutes of Health.

Our Position

Support

Original Sponsor 1

Co-Sponsors 19

Latest Actions See More/Less

  • June 13, 2018 — Received in the Senate and referred to the Senate Health, Education, Labor and Pensions Committee. Congressional Record p. S3904, S3905

  • June 12, 2018 — Measure passed in the House by voice vote, under suspension of the rules (two-thirds vote required). Congressional Record p. H5040

  • June 12, 2018 — Burgess, R-Texas, motion to suspend the rules and pass the bill, agreed to by voice vote. Congressional Record p. H5038-H5040

  • June 12, 2018 — Additional cosponsor(s): 3

    Jenkins, E. (R-W.Va.)Kilmer, (D-Wash.)McSally, (R-Ariz.)
  • June 8, 2018 — Additional cosponsor(s): 5

    Buck, (R-Colo.)Davis, R. (R-Ill.)Moolenaar, (R-Mich.)
    Coffman, (R-Colo.)Hill, (R-Ark.)
  • May 24, 2018 — Additional cosponsor(s): 4

    Clarke, Y. (D-N.Y.)Herrera Beutler, (R-Wash.)
    Donovan, (R-N.Y.)Walden, (R-Ore.)
  • May 15, 2018 — Additional cosponsor(s): 3

    Blackburn, M. (R-Tenn.)Latta, (R-Ohio)McKinley, (R-W.Va.)
  • May 9, 2018 — Full committee consideration and markup held by the House Energy and Commerce Committee.

    May 9, 2018 — Committee Vote: Unique Research Initiatives — Vote to Report

    Provide the National Institutes of Health with new, flexible authorities to conduct innovative research and spur research on new non-addictive pain medications. It would allow the NIH to conduct high impact cutting-edge research that fosters scientific creativity and increases fundamental biological understanding leading to the prevention, diagnosis, or treatment of diseases and disorders, or research urgently required to respond to a public health threat.

    Provide the National Institutes of Health with new, flexible authorities to conduct innovative research and spur research on new non-addictive pain medications. It would allow the NIH to conduct high impact cutting-edge research that fosters scientific creativity and increases fundamental biological understanding leading to the prevention, diagnosis, or treatment of diseases and disorders, or research urgently required to respond to a public health threat.

    Ordered reported favorably to the full House by voice vote.
  • April 25, 2018 — Subcommittee consideration and markup held by the House Energy and Commerce Committee, Subcommittee on Health.

    April 25, 2018 — Subcommittee Vote: Unique Research Initiatives — Vote to Approve

    Provide the National Institutes of Health with new, flexible authorities to conduct innovative research and spur research on new non-addictive pain medications. It would allow the NIH to conduct high impact cutting-edge research that fosters scientific creativity and increases fundamental biological understanding leading to the prevention, diagnosis, or treatment of diseases and disorders, or research urgently required to respond to a public health threat.

    Provide the National Institutes of Health with new, flexible authorities to conduct innovative research and spur research on new non-addictive pain medications. It would allow the NIH to conduct high impact cutting-edge research that fosters scientific creativity and increases fundamental biological understanding leading to the prevention, diagnosis, or treatment of diseases and disorders, or research urgently required to respond to a public health threat.

    Approved for full committee consideration by unanimous consent.
  • April 11, 2018 — Additional cosponsor(s): 2

    Fitzpatrick, (R-Pa.)Khanna, (D-Calif.)
  • March 6, 2018 — Additional cosponsor(s): 1

    Welch, (D-Vt.)
  • Feb. 13, 2018 — Original cosponsor(s): 1

    Upton, (R-Mich.)
  • Feb. 13, 2018 — Read twice and referred to: House Energy and Commerce.Congressional Record p. H1126

-->